Pharmacokinetic Study of Perioperative Intravenous Ifosfamide
暂无分享,去创建一个
[1] P. Sugarbaker,et al. Pharmacology of perioperative 5‐Fluorouracil , 2010, Journal of surgical oncology.
[2] D. Elias,et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Esquivel. Technology of Hyperthermic Intraperitoneal Chemotherapy in the United States, Europe, China, Japan, and Korea , 2009, Cancer journal.
[4] B. Moran,et al. Morbidity and Mortality With Cytoreductive Surgery and Intraperitoneal Chemotherapy: The Importance of a Learning Curve , 2009, Cancer journal.
[5] D. Elias,et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Colombo,et al. Combined treatment with local thermo-chemotherapy for non muscle invasive bladder cancer. The present role in the light of acquired data and preliminary cumulative clinical experiences. , 2008, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[7] F. Zoetmulder,et al. Learning curve of combined modality treatment in peritoneal surface disease , 2007, The British journal of surgery.
[8] P. Sugarbaker. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[9] H. Schlitt,et al. Continuous peritoneal perfusion: techniques, methods and applications. , 2007, Cancer treatment and research.
[10] J. Esquivel,et al. Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy , 2006, Annals of Surgical Oncology.
[11] Harm H. Kampinga,et al. Cell biological effects of hyperthermia alone or combined with radiation or drugs: A short introduction to newcomers in the field , 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[12] J. Lepock. How do cells respond to their thermal environment? , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[13] D. Dormont,et al. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. , 2004, European journal of gynaecological oncology.
[14] R. Issels,et al. Ifosfamide with Regional Hyperthermia in Soft-Tissue Sarcomas , 2003, Oncology.
[15] A. Lowy,et al. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. , 2003, Surgical oncology clinics of North America.
[16] R. Sticca,et al. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. , 2003, Surgical oncology clinics of North America.
[17] J. Pignon,et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] H. Groen,et al. Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites , 2001, Clinical Pharmacokinetics.
[19] Y. Nishimura,et al. For the clinical application of thermochemotherapy given at mild temperatures. , 1999, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[20] B. Schem,et al. Status of clinical hyperthermia. , 1999, Acta oncologica.
[21] H. Keizer,et al. High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[22] P. Sugarbaker,et al. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model , 1997, Cancer Chemotherapy and Pharmacology.
[23] P. Sugarbaker,et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy , 1996, Cancer.
[24] B. Teicher,et al. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. , 1995, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[25] K. Jablonski,et al. Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.
[26] J G McVie,et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. , 1990, Cancer chemotherapy and pharmacology.
[27] P. Wilkinson,et al. A simple quantitative HPLC assay for ifosfamide in biological fluids. , 1986, Biomedical chromatography : BMC.
[28] B. Barlogie,et al. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. , 1980, Cancer research.
[29] G. Hahn,et al. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[30] G. Hahn,et al. Thermochemotherapy: Synergism Between Hyperthermia (42-430) and Adriamycin (or Bleomycin) in Mammalian Cell Inactivation , 2022 .